4.21
0.05 (1.20%)
| Previous Close | 4.16 |
| Open | 4.33 |
| Volume | 106,699 |
| Avg. Volume (3M) | 177,940 |
| Market Cap | 217,665,840 |
| Price / Sales | 2.40 |
| Price / Book | 2.46 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -63.24% |
| Operating Margin (TTM) | -79.16% |
| Diluted EPS (TTM) | -0.980 |
| Quarterly Revenue Growth (YOY) | -9.10% |
| Total Debt/Equity (MRQ) | 52.12% |
| Current Ratio (MRQ) | 10.47 |
| Operating Cash Flow (TTM) | -24.17 M |
| Levered Free Cash Flow (TTM) | -8.84 M |
| Return on Assets (TTM) | -21.77% |
| Return on Equity (TTM) | -52.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Sight Sciences, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | -5.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | -2.70 |
|
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 20.93% |
| % Held by Institutions | 50.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kck Ltd. | 31 Dec 2024 | 4,374,975 |
| B Group, Inc. | 31 Mar 2025 | 833,600 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 4.00 (Morgan Stanley, -4.99%) | Hold |
| 4.00 (Piper Sandler, -4.99%) | Hold | |
| Median | 3.80 (-9.74%) | |
| Low | 3.00 (Lake Street, -28.74%) | Hold |
| Average | 3.65 (-13.30%) | |
| Total | 4 Hold | |
| Avg. Price @ Call | 3.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 15 Jul 2025 | 4.00 (-4.99%) | Hold | 3.34 |
| Piper Sandler | 18 Jun 2025 | 4.00 (-4.99%) | Hold | 4.27 |
| Citigroup | 22 May 2025 | 3.60 (-14.49%) | Hold | 3.28 |
| Lake Street | 09 May 2025 | 3.00 (-28.74%) | Hold | 3.08 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 May 2025 | Announcement | Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th |
| 08 May 2025 | Announcement | Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance |
| 24 Apr 2025 | Announcement | Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025 |
| 23 Apr 2025 | Announcement | Sight Sciences Announces the Release of its Sustainability Report |
| 22 Apr 2025 | Announcement | Sight Sciences Appoints Gary Burbach to its Board of Directors |
| 21 Apr 2025 | Announcement | Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |